Ipamorelin vs Rusfertide
Overview
Ipamorelin is primarily a performance & growth peptide, while Rusfertide is used for weight management & metabolic.
This page compares Ipamorelin and Rusfertide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Ipamorelin | Rusfertide | |
|---|---|---|
| Category | Performance & Growth | Weight Management & Metabolic |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 200-300 mcg | 19-108 mg |
| Frequency | twice-daily | once weekly, subcutaneous |
| Reported benefits | Natural GH release, improved body composition, better sleep, anti-aging effects, no appetite increase | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. |
| Reported side effects | Very well-tolerated. Rare: headache, injection site reactions | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. |
Key differences
Primary use. Ipamorelin is categorised under Performance & Growth, while Rusfertide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Ipamorelin: not FDA-approved; treated as a research compound. Rusfertide: FDA-approved.
Dosing. Ipamorelin is typically dosed at 200-300 mcg (twice-daily). Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous).
Can you stack them?
Some protocols combine peptides, but stacking Ipamorelin and Rusfertide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Ipamorelin and Rusfertide?
- Ipamorelin is primarily a performance & growth peptide, while Rusfertide is used for weight management & metabolic. Ipamorelin is not FDA-approved; generally classified as a research compound, whereas Rusfertide is FDA-approved for one or more indications.
- What is Ipamorelin used for?
- GH secretagogue, anti-aging.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- Can you take Ipamorelin and Rusfertide together?
- Some users combine peptides within a single protocol, but stacking Ipamorelin and Rusfertide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Ipamorelin or Rusfertide FDA-approved?
- Ipamorelin is not FDA-approved; generally classified as a research compound. Rusfertide is FDA-approved for one or more indications.
Read the full articles
- Ipamorelin — full monograph: mechanism, research, dosing & references
- Rusfertide — full monograph: mechanism, research, dosing & references